InVivo Biosystems was founded on deep CRISPR genome editing expertise. This enabled us to create custom genome-edited zebrafish and C. elegans.
In the years since, we have expanded our offerings to include preclinical studies and drug discovery studies. Now, our CRISPR genome editing platform can provide key insights which can de-risk your clinical trial, and/or decide the next phase of your product development.
Our core capabilities allow us to provide services including:
Building accurate genetically editing models using advanced CRISPR and other genetic engineering tools.
Examining the complete genetic and molecular profiles for determination of mechanism of action (MoA).
Replacing the native animal gene with the heterologous human gene for assessing function of an expressed human protein.
Determining a compound's effect on maintaining healthy aging by monitoring an animal throughout its lifespan.